Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence

about

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence

Item

http://www.wikidata.org/entity/Q58763037

description

article

@en

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Safety and efficacy of elbasvi ...... hepatitis C: current evidence

@en

Safety and efficacy of elbasvi ...... hepatitis C: current evidence

@nl

type

Item

label

Safety and efficacy of elbasvi ...... hepatitis C: current evidence

@en

Safety and efficacy of elbasvi ...... hepatitis C: current evidence

@nl

prefLabel

Safety and efficacy of elbasvi ...... hepatitis C: current evidence

@en

Safety and efficacy of elbasvi ...... hepatitis C: current evidence

@nl

P1476

Safety and efficacy of elbasvi ...... hepatitis C: current evidence

@en

P2093

Akihisa Nakamura

http://www.w3.org/2001/XMLSchema#string

Kenichi Morikawa

http://www.w3.org/2001/XMLSchema#string

Tomoe Shimazaki

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Replication of hepatitis C virus

Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes

The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.

Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.

Hepatitis C virus infection and dialysis: 2012 update.

Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-α in infectious virus production.

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

Hepatitis C virus NS5A: tales of a promiscuous protein.

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.

P304

2749-2756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S133697

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Naoya Sakamoto

P577

2018-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30233138

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

drug discovery

P932

6132225

http://www.w3.org/2001/XMLSchema#string